Compare KSS & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KSS | DFTX |
|---|---|---|
| Founded | 1962 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.7B |
| IPO Year | 1995 | N/A |
| Metric | KSS | DFTX |
|---|---|---|
| Price | $12.01 | $17.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $15.31 | ★ $40.25 |
| AVG Volume (30 Days) | ★ 4.7M | 1.4M |
| Earning Date | 03-10-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | $9.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.04 | $14.62 |
| 52 Week High | $25.22 | $19.62 |
| Indicator | KSS | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.12 | 49.91 |
| Support Level | $10.33 | $16.26 |
| Resistance Level | $16.95 | $18.21 |
| Average True Range (ATR) | 0.91 | 0.94 |
| MACD | -0.29 | -0.01 |
| Stochastic Oscillator | 1.72 | 35.34 |
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).